Paris-Saclay Seed Fund
VC Fund
San Francisco, United States
Paris-Saclay Seed Fund is a VC fund in San Francisco focused on Medical and Health Care. Paris Saclay Seed Fund was launched by Université Paris-Saclay and its members and operations were entrusted to two Venture Capital funds.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Paris-Saclay Seed Fund invests in
Stages Paris-Saclay Seed Fund invests in
Countries Paris-Saclay Seed Fund invests in
Round sizes
Round size
- Seed
- $2.3M–$3.3M
- Series A
- $5.7M–$18M
- Series B
- $8.8M–$22M
Investment Focus
Industry
- Medical 3 (38%)
- Health Care 3 (38%)
- Biotechnology 2 (25%)
- Medical Device 2 (25%)
- Fitness 1 (13%)
Stage
- Series A 3 (38%)
- Seed 2 (25%)
- Series B 2 (25%)
- Series C 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Stilla Technologies
|
Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System.Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all LifeSciences areas: research, therapeutics, and all the “omics”. | $26.5M / Series C / Feb 22, 2024 | |
DAMAE Medical
|
Damae Medical is a Paris, France-based medtech company. It has developed a medical device capable of seeing biological tissues in depth, at a cellular level and in vivo. This innovative optical imaging technology will especially allow dermatologists to evaluate in a precise, efficient and rapid way malignancy of tumors by a simple contact with thesurface of the skin. DAMAE Medical’s mission is to put the great power of bio-photonics at the service of opening new opportunities in medical imaging and diagnosis. | $5.7M / Series A / Feb 03, 2022 | |
|
Stilla Technologies
|
Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System.Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all LifeSciences areas: research, therapeutics, and all the “omics”. | $21.8M / Series B / Feb 11, 2020 | |
Sensome
|
Sensome develops a breakthrough remote monitoring technology that can turn invasive vascular medical devices into connected healthcare devices. By providing instantaneous and non-invasive identification of the tissue composition in contact with a medical device, Sensome's patent-pending sensor technology overcomes the limitations of vascularimaging techniques used in both interventions and patient follow-up. Sensome's team is currently developing vascular access devices equipped with the proprietary sensor technology, before eventually equipping implantable devices for neurovascular, peripheral vascular and cardiovascular indications. | $8.8M / Series B / Jan 12, 2020 | |
FeetMe
|
FeetMe is a medical company. Loss of mobility is a growing unmet medical need, 100 million people are suffering from mobility disorders worldwide. FeetMe has a mission to simplify and accelerate therapeutic and rehabilitation evaluations through continuous real life mobility assessment. FeetMe Monitor is a connected insole and an associated mobilesoftware that collects and analyze gait spatio-temporal parameters and variability in real life thanks to embedded smart algorithms and wireless connection. Their solution is sold to pharma companies for clinical trials, or to hospital and rehabilitation centers for mobility assessment and gait training and to patients for home rehabilitation. | $10.4M / Series A / Sep 24, 2019 | |
|
Stilla Technologies
|
Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System.Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all LifeSciences areas: research, therapeutics, and all the “omics”. | $18.3M / Series A / Nov 20, 2018 | |
|
FeetMe
|
FeetMe is a medical company. Loss of mobility is a growing unmet medical need, 100 million people are suffering from mobility disorders worldwide. FeetMe has a mission to simplify and accelerate therapeutic and rehabilitation evaluations through continuous real life mobility assessment. FeetMe Monitor is a connected insole and an associated mobilesoftware that collects and analyze gait spatio-temporal parameters and variability in real life thanks to embedded smart algorithms and wireless connection. Their solution is sold to pharma companies for clinical trials, or to hospital and rehabilitation centers for mobility assessment and gait training and to patients for home rehabilitation. | $2.3M / Seed / Oct 05, 2017 | |
|
Sensome
|
Sensome develops a breakthrough remote monitoring technology that can turn invasive vascular medical devices into connected healthcare devices. By providing instantaneous and non-invasive identification of the tissue composition in contact with a medical device, Sensome's patent-pending sensor technology overcomes the limitations of vascularimaging techniques used in both interventions and patient follow-up. Sensome's team is currently developing vascular access devices equipped with the proprietary sensor technology, before eventually equipping implantable devices for neurovascular, peripheral vascular and cardiovascular indications. | $3.3M / Seed / Jul 10, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Paris-Saclay Seed Fund invest in?
Paris-Saclay Seed Fund invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Paris-Saclay Seed Fund's check size?
Paris-Saclay Seed Fund typically joins rounds of $2.3M–$3.3M at Seed, $5.7M–$18M at Series A and $8.8M–$22M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Paris-Saclay Seed Fund participates in.
When did Paris-Saclay Seed Fund last invest?
The most recent investment recorded for Paris-Saclay Seed Fund closed in Feb 2024. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
